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Abstract
Background: Technological leaps in genome sequencing have resulted in a surge in discovery of human disease
genes. These discoveries have led to increased clarity on the molecular pathology of disease and have also
demonstrated considerable overlap in the genetic roots of human diseases. In light of this large genetic overlap, we
tested whether cross-disease research approaches lead to faster, more impactful discoveries.
Methods: We leveraged several gene-disease association databases to calculate a Mutual Citation Score (MCS) for
10,853 pairs of genetically related diseases to measure the frequency of cross-citation between research fields. To
assess the importance of cooperative research, we computed an Individual Disease Cooperation Score (ICS) and the
average publication rate for each disease.
Results: For all disease pairs with one gene in common, we found that the degree of genetic overlap was a poor
predictor of cooperation (r
2=0.3198) and that the vast majority of disease pairs (89.56%) never cited previous
discoveries of the same gene in a different disease, irrespective of the level of genetic similarity between the
diseases. A fraction (0.25%) of the pairs demonstrated cross-citation in greater than 5% of their published genetic
discoveries and 0.037% cross-referenced discoveries more than 10% of the time. We found strong positive
correlations between ICS and publication rate (r
2=0.7931), and an even stronger correlation between the
publication rate and the number of cross-referenced diseases (r
2=0.8585). These results suggested that cross-disease
research may have the potential to yield novel discoveries at a faster pace than singular disease research.
Conclusions: Our findings suggest that the frequency of cross-disease study is low despite the high level of
genetic similarity among many human diseases, and that collaborative methods may accelerate and increase the
impact of new genetic discoveries. Until we have a better understanding of the taxonomy of human diseases,
cross-disease research approaches should become the rule rather than the exception.
Background
The pace of genetic discovery in human diseases has
accelerated exponentially through the invention of high-
throughput technologies and the advent of next-
generation sequencing approaches. What were once
considered to be well-defined boundaries between
human diseases are increasingly appearing as arbitrary
and blurred. Recent research has shown that many
human diseases share large numbers of genes and
genetic networks, and therefore likely share molecular
mechanisms that will elucidate shared causes and shared
treatments [1].
This emerging picture of commonality among human
diseases suggests that research, in particular our collect-
ive understanding of the genetic causes of human dis-
eases, should benefit from a shift away from singularly
focused research towards multi-disease focused efforts
that look across existing disease circumscriptions rather
than within. Indeed, recent efforts have begun to prove
out this hypothesis, including comparative studies
among autism and related neurodevelopmental disorders
[2], as well as various disease-network approaches [3].
Such innovative approaches to the study of human
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genetically based taxonomy of disease.
In the present study, we capitalized on the last fifteen
years of genetic research to address whether or not
cross-pollination in genetic research of human diseases
has served to increase the pace of discovery. Specifically,
we constructed authoritative gene lists for 193 human
diseases defined in the Medical Subject Headings data-
base [4] and mapped the publication records for each
disease to the citation histories of all others. This
enabled us to track patterns of shared discovery and
evaluate the impact on the rate of new gene discovery in
cases where cross-disease research occurred, as well as
in cases where it did not.
Methods
The Mutual Citation Score
In order to quantify the degree of association between
the studies of biologically correlated disorders, we devel-
oped the Mutual Citation Score (MCS). The MCS
reflects the degree of relation between the genetic re-
search fields of two given diseases (i, j) based on the fre-
quency with which one disease field cites the work of
the other, and is defined by the following equation.
MCSij ¼
Cij þ Cji
Pi þ Pj
Cij= Number of citation events where a gene discovery
in disease i is cited back to the discovery of the same
gene in disease j
Cji= Number of citation events where a gene discovery
in disease j is cited back to the discovery of the same
gene in disease i
Pi= Total number of genetic publications in i
Pj= Total number of genetic publications in j
We attempted to control for self-citation by excluding
citation events where both publications had the same
last author. We computed the MCS for 10,853 disease
pairs that had at least one gene in common. Fundamen-
tally, for a pair of diseases, the MCS describes the per-
centage of all genetic discoveries that cross-reference the
other disease. Theoretically, the values for the MCS scale
from 0–1, where 0 signifies no record of cross-citations
between the two diseases. However, because the MCS is
based on the event when a gene is initially discovered in
a disease, it would be impossible to have a disease pair
with an MCS=1. For all 193 diseases, the research tool
Genotator [5] was used to provide gene lists and genetic
publication histories dated from 1996–2010 (Genotator
files obtained March 2011). Unrelated publications were
omitted from the publication histories of stroke,
asthma, hypersensitivity, leukemia, diabetes mellitus and
hemochromatosis after manual examination of the
abstracts revealed no mention of the disease. Publication
dates as well as author and citation information were
obtained via PubMed Entrez Utilities [6]. Although cit-
ation histories were only provided for PubMed Central
publications, this subset of 3868 articles supplied an ac-
curate representation of general research trends between
diseases. No disease was significantly under or overre-
presented in PubMed Central (Additional file 1: Table
S1) and the disorders were all treated equally using this
systematic approach.
The Individual Disease Cooperation Score
To determine the level of participation of any distinct
disease field in cooperative research, we calculated the
Individual Disease Cooperation Score (ICS) for each of
the 193 diseases studied. The ICS is a score that reflects
the amount of cooperative research that occurred in any
individual disease field (i) relative to all other diseases,
and is defined by the following equation:
ICSi ¼
X
MCSij
In other words, the ICS for any disease (i) is simply
the summation of all MCS(i,j) values for which (i) is part
of the disease pair (i, j).
Results
Genetic similarity does not predict cooperative research
We calculated the Mutual Citation Score (MCS), a
quantification of the degree to which one disease field
monitors the genetic discovery of another biologically
comparable disease. For 10,853 pairs of genetically
related diseases the overall genetic similarity between
two disorders was found not to be a consistent predictor
of MCS (r
2=0.3198) (Figure 1). Of all the disease pairs
studied for which there is an overlap of at least one
gene, over 99% cross-cited their identical genetic find-
ings less than 5% of the time (MCS < 0.05) and 89.56%
never cross-referenced their identical genetic findings
(MCS = 0) (Additional file 2: Table S2).
The disease pair of asthma and hypersensitivity, two
highly genetically related and co-morbid conditions
[7], returned the highest MCS of all disease pairs
(MCS=0.39297), translating to mutual citation in ap-
proximately 40% of all publications relevant to either
disorder. This pair shared 455 (74.71%) of their total
combined genes, and 1066 citation events were recorded
for 59 (13%) of the genes common to both disorders.
Among the cross-referenced genes were several known
to be high priority candidate genes in both asthma and
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ADRB2 [10].
Diabetes mellitus and obesity [11] had the second
highest MCS of 0.18314. The genetic overlap (35.7%)
between this pair consisted of 418 genes. We found
that 118 (28%) of the genes shared between diabetes
mellitus and obesity were cross-referenced between the
two research fields, including many genes that are strongly
linked to both diseases such as FTO [12], involved in
regulation of global metabolic rate and body fat accumula-
tion, as well as ADIPOQ [13], which is implicated in the
control of fat metabolism and insulin sensitivity.
We observed that a vast majority of disease pairs
(99.75%) returned MCS values lower than 0.05, irrespect-
ive of the amount of genetic overlap between the pair.
For example, lung neoplasms and bladder neoplasms
were found to share 431 genes (60.88%), the third highest
genetic overlap of all disease pairs examined. Less than
5% (n=21) of the genes common to both diseases were
cross-referenced, contributing to the comparatively low
MCS of 0.02578. Despite the low level of cooperative re-
search, many of the genes in common, including GSTM1
[14] and TP53 [15], have been shown to be highly asso-
ciated with the molecular pathology of both diseases.
A similar pattern was observed for bipolar disorder
and obsessive-compulsive disorder, two diseases not only
known to be genetically linked but also known to occur
together commonly in patients [16,17]. We found that
this disease pair had a genetic overlap of 53.48% consist-
ing of 307 genes, however the only cross-disease cita-
tions were for BDNF [18] and SLC6A4 [19], genes that
are widely implicated in over 300 other disorders and
potentially less directly related to the mechanistic causes
of disease than other genes. The resulting MCS for the
pair was 0.004732, thus mutual citation between the
fields of bipolar disorder and obsessive-compulsive dis-
order occurred in less than 0.5% of their combined set
of genetic publications.
Table 1 highlights the large variation of Mutual Citation
Scores for disease pairs with comparable genetic overlaps.
For example, the pair Parkinson disease and Gaucher dis-
ease had a genetic overlap of 2.57% and returned an MCS
of 0.064803, a very high MCS relative to other disease pairs
with a similar genetic overlap such as fragile X syndrome
and attention deficit disorder with hyperactivity (ADHD)
(MCS=0.002577) as well as α-1 antitrypsin deficiency and
lung neoplasms (MCS=0.000996). Also, many diseases that
had considerably higher levels of genetic overlap than the
Parkinson-Gaucher disease pair had much lower MCS
values, such as autism and ADHD (37.00% overlap,
MCS=0.003636), as well as myotonic dystrophy and fragile
X syndrome (40.00% overlap, MCS=0).
Figure 1 Mutual Citation Score of all disease pairs as compared with the biological association between the diseases (genetic overlap).
From this figure we can conclude that degree of cooperative research between a disease pair is not always indicative of the intensity of their
genetic relationship (r
2=0.3187).
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of genetic similarity. The disease pair of cryptococcosis,
a potentially fatal fungal infection, and poliomyelitis, the
viral infection commonly referred to as polio, had the
highest genetic overlap (75.00%) of all the disease pairs
studied. Despite its high genetic overlap, this pair was
found to have an MCS of 0, indicating that no inter-
disease collaboration has occurred throughout the
15 years covered in our analysis. However, asthma and
hypersensitivity, which had the next highest genetic
overlap (74.71%), returned the largest MCS value of any
disease pair by a significant margin (MCS=0.392971).
Figure 2 shows the gene interaction networks of diabetes
mellitus and obesity (A) as well as bladder neoplasms
and lung neoplasms (B). By comparing the two net-
works, we can see that both pairs share a considerable
number of important genes, but despite the similar gen-
etic relationships, the two pairs have largely different
patterns and histories of mutual citation.
Cross-pollination increases rate of discovery
To weigh the implications of cooperative research
efforts, we determined whether the presence or absence
of cooperation predicted the impact of genetic discovery
in general. Figure 3 illustrates a strong positive correl-
ation (r
2=0.7931) between the average rate of new dis-
covery (publications/day) of a disease and its Individual
Disease Cooperation Score (ICS), a measure of the total
Figure 2 The gene interaction networks of diabetes mellitus and obesity (A) as well as bladder neoplasms and lung neoplasms (B).
Orange nodes denote shared genes between the disorders. Even though the genetic overlap between the pairs is similar, the levels of mutual
citation are significantly different.
Table 1 Disease pairs with comparable genetic overlaps
have highly variable values for MCS
Disease pair Genetic overlap MCS
Parkinson Disease & Gaucher Disease 2.57% 0.064803
Fragile X Syndrome & ADHD 2.57% 0.002577
Obesity & Deafness 2.57% 0.000476
α-1 Antitrypsin Deficiency &
Lung Neoplasms
2.58% 0.000996
Rheumatic Fever & Rheumatic
Heart Disease
12.90% 0.170213
Hypertension & Breast Neoplasms 12.91% 0.003824
Cystic Fibrosis & Sarcoma 13.01% 0.000000
Ovarian Neoplasms & Breast
Neoplasms
29.47% 0.169344
Multiple Sclerosis & Rheumatoid
Arthritis
29.45% 0.027160
Spinal Muscular Atrophy &
Fragile X Syndrome
29.63% 0.000000
Diabetes Mellitus & Obesity 35.70% 0.183136
Autism & ADHD 37.00% 0.003636
Myotonic Dystrophy &
Fragile X Syndrome
40.00% 0.000000
Asthma & Hypersensitivity 74.71% 0.392971
Cryptococcosis & Poliomyelitis 75.00% 0.000000
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ease field (Additional file 3: Table S3). From this figure it
is clear that a disease research field publishes more fre-
quently when cross-referencing its gene discoveries with
another genetically related disease than a research field
that has worked independently despite high degrees
of genetic overlap with other diseases. We found
that disease fields that frequently referenced, or cross-
pollinated, published genetic discoveries in other disease
areas made novel genetic discoveries more rapidly than
non-cooperative diseases, resulting in a complete genetic
disease profile sooner. The observed correlation between
the ICS and publication rate did not appear to be due to
a “genetic bandwagon” effect in which disease fields fol-
low the research trends of more active areas of research
and discovery. When examining the balance in the num-
ber of citations from one disease to another for all dis-
ease pairs (limiting to those with 20 or more total
citations), we found that a majority (61%) had near even
numbers of co-citations, with 75% or more of the com-
bined total evenly distributed between the two diseases
in a pair (Additional file 4: Table S4).
The three disease fields that published most often
were found to be diabetes mellitus, hypertension and
obesity. Diabetes mellitus was found to have a publica-
tion rate of 0.87089 publications per day, translating to
approximately 320 publications per year. Similarly, we
calculated that the field of hypertension produces about
220 publications every year (pub rate=0.59701) and obe-
sity, on average, releases 185 genetic publications per
year (pub rate=0.05788). These diseases were also among
the top fifteen most cooperative disease fields, as calcu-
lated by the ICS.
Furthermore, we determined that the number of co-
operative partnerships was also highly correlated with
the publication success of a given disease field
(r
2=0.8585), as depicted in Figure 4. Hypertension, dia-
betes mellitus and breast neoplasms were each found to
have 72, 65, and 63 cooperative relationships, respect-
ively. These were three of the top four most prolific
fields we studied, in terms of publication rate. These
data suggest that not only was the amount of cross-
disease collaboration important for accelerating discov-
ery, but that variety in collaborative partnerships also
contributed to a faster rate of novel discovery.
The opposite was observed for disease fields that colla-
borated infrequently, or not at all, with related disease
fields. These diseases were substantially slower at pub-
lishing novel genetic discoveries. For example, fragile X
syndrome had a low publication rate of 0.018222 publi-
cations per day, or about six publications per year, as
well as a poor ICS (ICS=0.1881). Likewise, fragile X syn-
drome was found to have only cited six of 70 related dis-
ease fields in its history of genetic publications. We also
Figure 3 Average rate of publication (publications/day) of disease-specific research fields with various levels of involvement in
cooperative research (defined by the ICS). From this figure it is clear that two genetically related diseases publish more often when
cross-referencing their gene discoveries (diabetes mellitus and obesity), than when working independently (autism and ADHD) (r
2=0.7931).
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other disease field in its genetic research, despite having
high genetic overlap with over 40 diseases, including
spinal muscular atrophy (38.10%) and fragile X syn-
drome (40.00%). As a consequence of this low level of
inter-disease collaboration, myotonic dystrophy had a
publication rate of 0.007194, translating to an average of
only two or three genetic publications per year. This dis-
covery rate is more than 100 times slower than that of
diabetes mellitus, the leader in genetic publication, even
though diabetes and obesity, the relationship that contri-
butes most to diabetes mellitus’ ICS, share only 35.70%
of their implicated genes, less than myotonic dystrophy
shares with either spinal muscular atrophy or fragile X
syndrome. Our data provides evidence that disease fields
such as myotonic dystrophy and fragile X syndrome
could greatly improve their publication rates by partici-
pating in more cooperative research.
Discussion
By analyzing the publication histories of 193 genetic
disorders over the last fifteen years, we found that cross-
pollination of genetic discovery, or cross-disease re-
search, is uncommon. Surprisingly, only 0.25% of all
genetically related disease pairs studied exhibited inter-
disease collaboration in greater than 5% of their total
genetic research (MCS ≥0.05), and only about 10% of all
disease pairs participated in cooperative research at any
level (MCS >0.00), despite often large numbers of genes
in common between the diseases.
We also found that when cross-pollination of genetic
discovery does occur, the pace of discovery in the field is
accelerated. Both the number of collaborative relation-
ships – the number of different diseases whose research
was cited by a genetically similar disease – and the Indi-
vidual Disease Cooperation Score (ICS) were found to
have significant positive correlations with publication
rate. These results indicate that diseases that engage in
collaborative research frequently and with a wide variety
of related diseases tend to publish genetic discoveries
more quickly than non-cooperative disease fields. Be-
cause the balance in co-citation among a majority of the
disease pairs studied was high, we can conclude that the
correlation between cross-pollination and accelerated
discovery was due to a bidirectional sharing of research
findings rather than a gene bandwagon effect and unidir-
ectional tracking of “hot” disease fields.
Our results suggest that the field of human disease re-
search has historically functioned mainly in a discon-
nected and single-disease focused manner rather than
through collaborative multi-disease spanning effort. Part
of this no doubt stems from our existing taxonomy of
human disease and the importance of specialization, and
potentially also to the funding priorities of federal fund-
ing agencies. However, our study provides evidence in
support of the possible benefits of a shift towards more
Figure 4 Average rate of publication (publications/day) of disease-specific research fields with various numbers of cooperative
partnerships. From this figure it is clear that diseases publish more frequently when cooperating with a larger variety of genetically related
diseases (r
2=0.8585).
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discoveries made by cross-disease collaborations could
provide insight into multi-disease indications for drugs,
and since fields that participate in cross-disease colla-
borations tend to make discoveries faster, such a strategy
would accelerate the beginning of clinical trials for these
newly proposed therapies.
Conclusions
The present study demonstrates the benefits of a cross-
disease research model for genetic research in human
diseases as they are currently defined. We found that a
vast majority of genetically related diseases show no evi-
dence for collaborative research practices over the last
fifteen years. However, we observed that both the
amount of cooperative research and the number of col-
laborative relationships in a particular disease field
showed a strong positive correlation with an accelerated
discovery rate in that disease field. These results suggest
that cross-disease research will become increasingly
more common and could accelerate the pace of discov-
ery in the field as a whole, leading to faster understand-
ing of the genetic roots of disease, faster development of
multi-indicated drugs, and perhaps also leading to a new
taxonomy of human disease that is informed by the ex-
pansive overlap in underlying genetic composition rather
than by symptomatic traits.
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